Health Care

Manufacturers of health care equipment and devices. Includes medical instruments, drug delivery systems, cardiovascular & orthopedic devices, and diagnostic equipment.

Manufacturers of health care supplies and medical products not classified elsewhere. Includes eye care products, hospital supplies, and safety needle & syringe devices.

Distributors and wholesalers of health care products not classified elsewhere.

Providers of patient health care services not classified elsewhere. Includes dialysis centers, lab testing services, and pharmacy management services. Also includes companies providing business support services to health care providers, such as clerical support services, collection agency services, staffing services and outsourced sales & marketing services.

Owners and operators of health care facilities, including hospitals, nursing homes, rehabilitation and retirement centers and animal hospitals.

Owners and operators of Health Maintenance Organizations (HMOs) and other managed plans.

Companies providing information technology services primarily to health care providers. Includes companies providing application, systems and/or data processing software, internet-based tools, and IT consulting services to doctors, hospitals or businesses operating primarily in the Health Care sector.

Companies primarily engaged in the research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering. Includes companies specializing in protein-based therapeutics to treat human diseases. Excludes companies manufacturing products using biotechnology but without a health care application.

Companies engaged in the research, development or production of pharmaceuticals. Includes veterinary drugs.

Companies enabling the drug discovery, development and production continuum by providing analytical tools, instruments, consumables & supplies, clinical trial services and contract research services. Includes firms primarily servicing the pharmaceutical and biotechnology industries.

https://www.spcapitaliq.com/gicsmaps

Income Statment

  2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Revenue 20,561,723,000 17,303,243,000 16,149,356,000 14,820,371,000 13,298,781,000 12,092,538,000 10,584,755,000 10,053,211,000 9,187,194,000 8,741,012,000
Cost of Goods Sold -6,493,731,000 -5,386,173,000 -5,107,588,000 -4,811,011,000 -4,508,181,000 -4,180,059,000 -3,532,176,000 -3,449,258,000 -3,124,703,000 -3,256,705,000
Gross Profit 14,067,992,000 11,917,070,000 11,041,768,000 10,009,360,000 8,790,600,000 7,912,479,000 7,052,579,000 6,603,953,000 6,062,491,000 5,484,307,000
Operating Costs -8,642,780,000 -8,650,856,000 -7,359,348,000 -6,585,235,000 -6,062,221,000 -5,357,593,000 -4,553,328,000 -4,243,886,000 -3,860,144,000 -3,602,460,000
Operating Profit 5,425,212,000 3,266,214,000 3,682,420,000 3,424,125,000 2,728,379,000 2,554,886,000 2,499,251,000 2,360,067,000 2,202,347,000 1,881,847,000
Financing Costs -267,819,000 -265,551,000 -253,463,000 -185,444,000 -154,011,000 -147,075,000 -125,633,000 -123,687,000 -119,070,000 -121,762,000
Pre-Tax Profit 5,157,393,000 3,000,663,000 3,428,957,000 3,238,681,000 2,574,368,000 2,407,811,000 2,373,618,000 2,236,380,000 2,083,277,000 1,760,085,000
Income Tax -1,108,235,000 -594,560,000 -674,488,000 -778,916,000 -570,932,000 -510,489,000 -494,741,000 -446,811,000 -394,746,000 -361,697,000
Net Profit 4,049,158,000 2,406,103,000 2,754,469,000 2,459,765,000 2,003,436,000 1,897,322,000 1,878,877,000 1,789,569,000 1,688,531,000 1,398,388,000

Balance Sheet

  2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Current Assets 10,904,273,000 10,378,805,000 7,928,284,000 6,809,609,000 6,490,503,000 5,497,781,000 4,847,828,000 4,541,498,000 4,516,987,000 4,533,737,000
Non-Current Assets 21,451,818,000 19,788,725,000 15,725,150,000 13,322,725,000 11,646,721,000 10,392,901,000 8,770,933,000 8,322,844,000 7,741,240,000 6,998,910,000
Assets 32,356,091,000 30,167,530,000 23,653,434,000 20,132,334,000 18,137,224,000 15,890,682,000 13,618,761,000 12,864,342,000 12,258,227,000 11,532,647,000
Current Liabilities 5,724,037,000 5,029,133,000 4,397,084,000 3,070,263,000 3,578,363,000 2,845,939,000 1,927,690,000 2,036,072,000 2,123,069,000 2,193,678,000
Non-Current Liabilities 10,044,711,000 11,544,899,000 7,787,284,000 8,088,446,000 6,925,284,000 6,296,277,000 5,262,787,000 4,228,071,000 3,853,344,000 2,867,190,000
Liabilities 15,768,748,000 16,574,032,000 12,184,368,000 11,158,709,000 10,503,647,000 9,142,216,000 7,190,477,000 6,264,143,000 5,976,413,000 5,060,868,000
Equity 16,587,343,000 13,593,498,000 11,469,066,000 8,973,625,000 7,633,577,000 6,748,466,000 6,428,284,000 6,600,199,000 6,281,814,000 6,471,779,000

Cash Flow Statement

  2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Cash Flow from Operating Activities 5,936,036,000 3,690,798,000 2,787,708,000 2,928,120,000 2,242,737,000 2,071,421,000 2,064,385,000 2,028,475,000 1,840,886,000 1,860,838,000
Cash Flow from Financing Activities -3,851,558,000 -24,936,000 55,266,000 -1,037,619,000 -123,229,000 -361,441,000 -1,196,290,000 -1,425,291,000 -1,432,510,000 -481,899,000
Cash Flow from Investing Activities -1,785,950,000 -2,211,317,000 -2,524,429,000 -2,053,936,000 -1,671,992,000 -1,646,471,000 -730,716,000 -772,816,000 -758,503,000 -695,380,000
Net Change in Cash 298,528,000 1,454,545,000 318,545,000 -163,435,000 447,516,000 63,509,000 137,379,000 -169,632,000 -350,127,000 683,559,000
Cash at the Beginning of the Period 2,946,449,000 1,473,046,000 1,187,468,000 1,370,117,000 921,153,000 877,101,000 894,564,000 1,032,218,000 1,405,180,000 761,710,000
Exchange Fluctuations -5,450,000 18,858,000 -32,967,000 -19,214,000 1,488,000 -19,457,000 -154,842,000 31,978,000 -22,835,000 -40,089,000
Cash at the End of the Period 3,239,527,000 2,946,449,000 1,473,046,000 1,187,468,000 1,370,157,000 921,153,000 877,101,000 894,564,000 1,032,218,000 1,405,180,000

Profitability

  2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Gross Margin 68.4% 68.9% 68.4% 67.5% 66.1% 65.4% 66.6% 65.7% 66.0% 62.7%
Operating Margin 26.4% 18.9% 22.8% 23.1% 20.5% 21.1% 23.6% 23.5% 24.0% 21.5%
Net Margin 19.7% 13.9% 17.1% 16.6% 15.1% 15.7% 17.8% 17.8% 18.4% 16.0%

Management Effectiveness

  2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Return on Assets 12.5% 8.0% 11.6% 12.2% 11.0% 11.9% 13.8% 13.9% 13.8% 12.1%
Return on Equity 24.4% 17.7% 24.0% 27.4% 26.2% 28.1% 29.2% 27.1% 26.9% 21.6%
Current Ratio 1.9 2.1 1.8 2.2 1.8 1.9 2.5 2.2 2.1 2.1
Debt to Equity Ratio 0.3 0.4 0.4 0.3 0.5 0.4 0.3 0.3 0.3 0.3

Valuation

  2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Share Price ($) 164.90 157.99 124.09 116.71 87.80 72.24 57.75 45.10 41.86 30.10
Ordinary Shares 998,791,142 994,912,490 984,802,022 934,625,512 929,867,545 928,900,712 923,901,849 932,661,845 941,661,295 952,289,154
Market Capitalisation ($) 164,695,986,078 157,181,917,043 122,206,725,416 109,078,110,697 81,642,074,349 67,103,563,393 53,359,666,285 42,063,950,201 39,419,829,742 28,664,467,784
Revenue per Share ($) 20.59 17.39 16.40 15.86 14.30 13.02 11.46 10.78 9.76 9.18
Earnings per Share ($) 4.05 2.42 2.80 2.63 2.15 2.04 2.03 1.92 1.79 1.47
Equity per Share ($) 16.61 13.66 11.65 9.60 8.21 7.27 6.96 7.08 6.67 6.80
Dividends per Share ($) 1.54 1.40 1.41 1.27 1.15 1.07 1.01 0.96 0.91 0.82
Dividend Yield 0.9% 0.9% 1.1% 1.1% 1.3% 1.5% 1.8% 2.1% 2.2% 2.7%
Price to Sales Ratio 8.0 9.1 7.6 7.4 6.1 5.5 5.0 4.2 4.3 3.3
Price to Earnings Ratio 40.7 65.3 44.4 44.3 40.8 35.4 28.4 23.5 23.3 20.5
Price to Book Ratio 9.9 11.6 10.7 12.2 10.7 9.9 8.3 6.4 6.3 4.4